Please assess the completion status of the following clinical trial:

Trial Title: The PK/PD Study of SHR2285 Tablets in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. males or females, aged 18-45~2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP\<140mmHg and 50mmHg ≤DBP\<90mmHg;~3. body mass index (BMI) between 18 to 28, and a total body weight: male ≥50.0 kg and \<90.0 kg; female ≥45.0 kg and \<90.0 kg~4. Participant in general good health. No clinically significant findings in laboratory parameters or clinically significant abnormality on X-ray~Exclusion Criteria:~1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin \> 1X ULN during screening/baseline;~2. Abnormal coagulation function;~3. A clinical history of coagulation dysfunction；subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.~4. Subjects with severe trauma or surgery within 3 months prior to the screening；~5. Known blood donation within 30 days pre-dose; donating≥400 ml of blood 3 months pre-dose;~6. Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive;~7. 3 months prior to screening involved in any drug or medical device clinical subjects, or within 5 half-life of drugs before screening;~8. Pregnant or Serum β-hCG \> 5mIU/mL at baseline or women who are breastfeeding; etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- SHR2285 (Type: EXPERIMENTAL): Up to 7 cohorts of healthy subjects will receive a single dose of oral SHR2285 tablet.
- Placebo (Type: EXPERIMENTAL): Up to 7 cohorts of healthy subjects will receive a single dose of oral placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).